{"id":"hetrombopag-olamine-standard-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Bone marrow fibrosis"}]},"_chembl":{"chemblId":"CHEMBL4297764","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hetrombopag binds to and activates the thrombopoietin (TPO) receptor on megakaryocyte progenitor cells, promoting their proliferation and differentiation into mature megakaryocytes, which subsequently release platelets into the bloodstream. This mechanism increases circulating platelet counts in patients with thrombocytopenia. When combined with standard therapy, it may enhance treatment efficacy in conditions where low platelet counts limit therapeutic options.","oneSentence":"Hetrombopag olamine is a thrombopoietin receptor agonist that stimulates platelet production to increase platelet counts.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:03.475Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune thrombocytopenia (ITP)"},{"name":"Thrombocytopenia in patients with chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT03825744","phase":"PHASE3","title":"Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-03-05","conditions":"Severe Aplastic Anemia","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hetrombopag Olamine+Standard Therapy","genericName":"Hetrombopag Olamine+Standard Therapy","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hetrombopag olamine is a thrombopoietin receptor agonist that stimulates platelet production to increase platelet counts. Used for Immune thrombocytopenia (ITP), Thrombocytopenia in patients with chronic hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}